Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Mars spacecraft images pinpoint comet 3I/ATLAS's path with 10x higher accuracy. This could help us protect Earth someday - 2How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
- 310 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- 4Get To Be familiar with The Historical backdrop Of Western Medication
- 5Hot Electric Vehicles for 2023
- Old food pyramid vs. RFK Jr.'s new food pyramid. See what's different.
- Ten Awesome Authentic Realities That Will Leave You Interested
- 4 buzzy new TV shows to watch — plus the return of 'The Comeback,' 'Jury Duty' and more
- Artemis moon mission breaks record for distance from Earth
- A top Marine shares his secrets to keeping fit at 50
- Treasure trove found in Egyptian tomb solves ancient mystery
- The race is on to turn your body into a GLP-1 factory
- One month of war on Iran cost Arab countries up to $194bn: UNDP
- Federal judge upholds Hawaii's new climate change tax on cruise passengers
